MAASTRICHT, Netherlands, June 18, 2024 /PRNewswire/ -- Pie Medical Imaging, a global leader in cardiac imaging, announced the completion of enrollment in FASTIII, a multi-center randomized clinical trial, which investigates the use of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures. vFFR can assess whether a coronary artery narrowing is functionally significant and may require revascularization.

FASTIII is the largest non-inferiority trial running (having enrolled 2228 patients), in which an angiographically derived vFFR guided strategy is compared to a FFR guided strategy to guide coronary revascularization. The primary endpoint is a composite of all-cause death, any myocardial infarction, or any revascularization at 1-year post randomization.

Following the tremendous efforts of the principal investigator, Dr Joost Daemen (cardiologist at Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The Netherlands), over 35 participating centers and ECRI (sponsor of the trial), the patient enrollment has concluded.

"The FASTIII trial is aimed to establish the role of vFFR to coronary revascularization in patients with intermediate coronary artery lesions. An important milestone was reached Friday, May 31^st, 2024, when the last patient was enrolled", said Joost Daemen Principal Investigator of the trial. "The next phase will consist of close follow-up of all patients who generously agreed to participate in the important trial. We hope to present our findings by the end of 2025".

Additionally,

"PMI is committed to providing clinicians and patients with long-term coronary data to inform their treatment decisions, " said René Guillaume, Managing Director at Pie Medical Imaging. "Our prior studies have shown diagnostic accuracy and reproducibility of vFFR calculation". FASTIII will establish its role in routine clinical practice.

The trial is funded by research grants from Pie Medical Imaging (Maastricht, The Netherlands) and Siemens Healthineers (Erlangen, Germany). The study is sponsored by ECRI (European Cardiovascular Research Institute, Rotterdam-the Netherlands). Cardialysis (Rotterdam, The Netherlands) is responsible for trial services including trial management and Core Laboratory activities.

About Pie Medical Imaging

Pie Medical Imaging BV is a world leader in analysis and visualization of cardiovascular images. In Maastricht (The Netherlands), it hosts the global sales for the CAAS and 3mensio product lines.

PMI and 3mensio Medical Imaging part of the Esaote Group, leader in the biomedical equipment sector. More information about PMI is available at www.piemedicalimaging.com

Photo -
Logo -

View original content:https://www.prnewswire.co.uk/news-releases/pie-medical-imaging-announces-enrollment-completion-of-the-fastiii-clinical-trial-302172284.html

Images

Tags

More Like This

CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial

CathWorks Announces EU MDR Approval, Prominent Presence at EuroPCR and Full Launch of Co-promotion

FIELD MEDICAL ANNOUNCES FIRST-IN-HUMAN DATA FOR FOCAL PFA IN SCAR-RELATED VT AT HEART RHYTHM 2025

Imricor Commences VISABL-VT Trial

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

Imricor’s VISABL-AFL Trial for US FDA Approval Commences at Cardiovascular Institute of South Paris

Field Medical, Inc. Announces Oversubscribed Seed Round to Advance Next-Generation Cardiac Ablation Technology

FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD ABLATION FOR VENTRICULAR TACHYCARDIA